Novelstem Q2 net loss narrows to $85,795 from year-ago profit
NSTM•Q2 and six-month results
- Novelstem posted a net loss of $140,816 for the six months ended June 30, 2026, swinging from net income of $2.55 million.
- Net loss was $85,795 for the three months ended June 30, 2026, turning from net income of $2.75 million.
- G&A expense fell 74.83% to $39,888 for the six-month period, driven by lower professional fees and discounted settlement of prior legal fees.
- Interest expense declined 38.44% to $100,928 for the six months, following the May 9, 2025 settlement of the litigation funding agreement.
- Current assets rose to about $65,000 at June 30, 2026, reflecting equity sales; current liabilities eased to $2.1 million.
